N-<3-Brom-phenyl>-N'-methyl-harnstoff | 20940-44-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-<3-Brom-phenyl>-N'-methyl-harnstoff
• 英文别名: N-(3-bromo-phenyl)-N'-methyl-urea；N-(3-Brom-phenyl)-N'-methyl-harnstoff；1-(3-Bromophenyl)-3-methylurea
• CAS: 20940-44-7
• 化学式: C₈H₉BrN₂O
• mdl: MFCD00027983
• 分子量: 229.076
• InChiKey: WSWUINCWBBKAGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-<3-Brom-phenyl>-N'-methyl-harnstoff 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 氢气 、 乙酸酐 、 三乙胺 、 sodium nitrite 、 二苯基次膦酰氯 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 17.0h， 生成 N-[6-amino-1-(3-bromophenyl)-3-methyl-2,4-dioxopyrimidin-5-yl]-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxamide
  参考文献：
  名称：

  Structure and activity relationships of novel uracil derivatives as topical anti-inflammatory agents

  摘要：

  In order to create novel, topical anti-inflammatory compounds exhibiting more potent activities than lead compound CX-659S (1), we designed and synthesized various derivatives of 1 focusing on the uracil N(l)- and N(3)-substituents, and evaluated their anti-inflammatory activities via inhibition of the picryl chloride-induced contact hypersensitivity reaction (CHR) in mice. In the course of our structure and activity relationship study, we found that compounds 6k, 6q, and 6r inhibited by approximately 50% the CHR, at 0.1 mg/ear. These activities were essentially equipotent with that of Tacrolimus, a strong immunosuppressant. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.012
• 作为产物：
  描述：

  间溴苯胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 42.0h， 生成 N-<3-Brom-phenyl>-N'-methyl-harnstoff
  参考文献：
  名称：

  COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF

  摘要：

  公开号：

  EP3643308B1

文献信息

• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US20180179151A1

  公开（公告）日：2018-06-28

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，表现出促进俄利班受体活性，并且预计可用作嗜睡症等疾病的预防或治疗药物。本发明提供一种由式(I)表示的化合物：其中每个符号如描述中定义，或其药用可接受的酸盐，具有促进俄利班受体活性，并且含有该化合物或其药用可接受的酸盐的俄利班受体激动剂。
• 17,20-Lyase inhibitors. Part 3: Design, synthesis, and structure–activity relationships of biphenylylmethylimidazole derivatives as novel 17,20-lyase inhibitors
  作者：Tomohiro Kaku、Saori Tsujimoto、Nobuyuki Matsunaga、Toshimasa Tanaka、Takahito Hara、Masuo Yamaoka、Masami Kusaka、Akihiro Tasaka

  DOI：10.1016/j.bmc.2011.02.009

  日期：2011.4

  A novel series of biphenylylmethylimidazole derivatives and related compounds were synthesized as inhibitors of 17,20-lyase, a key enzyme in the production of steroid hormones, and their biological activities were evaluated. In an attempt to identify potent and selective inhibitors of 17,20-lyase over the related CYP3A4 enzyme, a homology model for human 17,20-lyase was developed using the X-ray crystallographic

  合成了一系列新颖的联苯甲酰基甲基咪唑衍生物和相关化合物，作为类固醇激素生产中的关键酶17,20-裂合酶的抑制剂，并对其生物学活性进行了评估。为了确定17,20-裂解酶对相关CYP3A4酶的有效和选择性抑制剂，使用哺乳动物CYP2C5酶的X射线晶体学结构开发了人17,20-裂解酶的同源性模型。借助分子建模，对联苯部分进行了优化，得到了乙酰胺衍生物，将其通过HPLC拆分，得到了活性（-）-对映异构体。所获得的活性对映异构体不仅显示出对大鼠和人的17,20-裂合酶均具有有效的抑制作用，且IC 50值分别为14和26 nM，但对CYP3A4抑制17,20-裂解酶的选择性也极好（> 300倍）。此外，单只口服给药后，该活性对映异构体可显着降低猴子模型中的血清睾丸激素和DHEA浓度。活性对映体的不对称合成也通过使用非对映选择性格氏反应的手性中间体进行。
• FATTY ACID SYNTHASE INHIBITORS
  申请人：Adams Nicholas D.

  公开号：US20130172384A1

  公开（公告）日：2013-07-04

  This invention relates to the use of triazolone and triazolethione derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones and triazolethiones in the treatment of cancer.

  本发明涉及三唑酮和三唑硫醇衍生物的使用，用于调节，尤其是抑制脂肪酸合成酶（FAS）的活性或功能。适当地，本发明涉及三唑酮和三唑硫醇在治疗癌症方面的应用。
• Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US10351522B2

  公开（公告）日：2019-07-16

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，该化合物具有奥曲肽受体激动剂活性，有望用作嗜睡症等的预防或治疗药物。本发明提供了一种由式（I）代表的化合物： 其中各符号如描述中所定义，或其药学上可接受的酸加成盐，具有奥曲肽受体激动剂活性，以及含有该化合物或其药学上可接受的酸加成盐的奥曲肽受体激动剂。
• Boehmer, Recueil des Travaux Chimiques des Pays-Bas, 1936, vol. 55, p. 379,383
  作者：Boehmer

  DOI：——

  日期：——